First New York Securities’s Emergent Biosolutions EBS Stock Holding History

First New York Securities’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-5,000	Closed	-$126K	–	240
2014 Q1	$126K	Buy	+5,000	New	+$126K	0.06%	196
2013 Q3	–	Sell	-55,300	Closed	-$797K	–	380
2013 Q2	$797K	Buy	+55,300	New	+$801K	0.3%	66

Other funds holding EBS

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

First New York Securities's EBS Position: Q2 2014 in Review

First New York Securities sold out of Emergent Biosolutions (EBS) in Q2 2014, closing a stake of 5,000 shares — an estimated $126K sold.

First New York Securities first reported a position in EBS in Q2 2013 and held it in 2 quarters. The position peaked at $797K in Q2 2013. 160 funds tracked by Wall St. Rank hold EBS as of Q2 2014.

First New York Securities reported no remaining Emergent Biosolutions position as of Q2 2014 after selling out during the quarter.
First New York Securities sold 5,000 Emergent Biosolutions shares in Q2 2014, an estimated $126K.
First New York Securities first reported a position in Emergent Biosolutions in Q2 2013 and held it in 2 quarters.
First New York Securities's Emergent Biosolutions position peaked at $797K in Q2 2013.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2014.

Based on First New York Securities's 13F filing for Q2 2014, filed 15 Aug 2014.